<DOC>
	<DOCNO>NCT00002239</DOCNO>
	<brief_summary>The purpose study see safe effective give T-20 , new type anti-HIV drug , combination anti-HIV drug . The anti-HIV drug use abacavir ( ABC ) , amprenavir ( APV ) , ritonavir ( RTV ) , efavirenz ( EFV ) . Three different dos T-20 test .</brief_summary>
	<brief_title>A Study Compare Three Doses T-20 When Given Combination With Abacavir , Amprenavir , Ritonavir , Efavirenz HIV-Infected Adults</brief_title>
	<detailed_description>Patients assign one four group . Three dose group receive background antiretroviral regimen ( ABC , APV , RTV , EFV ) T-20 , give one three dose twice-daily regimen . The fourth group ( control ) receive background antiretroviral regimen alone . For treatment group , 17 patient enrol . Treatment administer 16 week , follow 32-week treatment extension , 2-week follow-up period . The follow assess throughout trial : safety parameter ( measure hematology , clinical chemistry , urinalysis , treatment-emergent adverse event ) ; virologic immunologic activity ; phenotypic genotypic resistance ; T-20 plasma level ; pharmacokinetics T-20 oral antiretrovirals . The total study duration 1 year .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have HIV level ( viral load ) 400 100,000 copies/ml screen visit . Have take least 1 PI ( protease inhibitor ) least 16 week , interruption recent PIcontaining antiHIV drug regimen . Are least 18 year old . Agree abstinence use 2 effective method birth control , include barrier method , study . Exclusion Criteria Patients eligible study : Have ever take NNRTI ( nonnucleoside reverse transcriptase inhibitor ) . Have opportunistic ( HIVrelated ) infection . Have unexplained fever least 38.5 C 7 day row within 30 day prior screen . Have diarrhea lasting least 15 day within 30 day prior screen . Have ever take abacavir , amprenavir , efavirenz ( ABC , APV , EFV ) . Have certain genetic characteristic ( drug resistance mutation ) could change way drug act body . Are allergic study medication . Have tumor certain skin cervical cancer . Are chemotherapy discontinue study . Are take investigational drug within 30 day prior screen . Have ever receive HIV vaccine . Are take certain medication . Abuse drug alcohol . Have hemophilia another blood clot disorder . Have organ transplant . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>VX 478</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>pentafuside</keyword>
	<keyword>abacavir</keyword>
	<keyword>efavirenz</keyword>
</DOC>